The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 2007−2011
Open accessAbstract
Background Skin cancer, the most common cancer in the U.S., is a major public health problem. The incidence of nonmelanoma and melanoma skin cancer is increasing; however, little is known about the economic burden of treatment. Purpose To examine trends in the treated prevalence and treatment costs of nonmelanoma and melanoma skin cancers. Methods This study used data on adults from the 2002–2011 Medical Expenditure Panel Survey full-year consolidated files and information from corresponding medical conditions and medical event files to estimate the treated prevalence and treatment cost of nonmelanoma skin cancer, melanoma skin cancer, and all other cancer sites. Analyses were conducted in January 2014. Results The average annual number of adults treated for skin cancer increased from 3.4 million in 2002–2006 to 4.9 million in 2007–2011 (p<0.001). During this period, the average annual total cost for skin cancer increased from $3.6 billion to $8.1 billion (p=0.001), representing an increase of 126.2%, while the average annual total cost for all other cancers increased by 25.1%. During 2007–2011, nearly 5 million adults were treated for skin cancer annually, with average treatment costs of $8.1 billion each year. Conclusions These findings demonstrate that the health and economic burden of skin cancer treatment is substantial and increasing. Such findings highlight the importance of skin cancer prevention efforts, which may result in future savings to the healthcare system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A systematic review of worldwide incidence of nonmelanoma skin cancer
Lomas, A., Leonardi‐Bee, J., & Bath‐Hextall, F. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10830.x · Cited by 1,937
Edwards, B. K., Noone, A., Mariotto, A. B., Simard, E. P., Boscoe, F. P., Henley, S. J., Jemal, A., Cho, H., Anderson, R. N., Kohler, B. A., et al. (2014) · Cancer · doi:10.1002/cncr.28509 · Cited by 1,210
Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006
Rogers, H. W., Weinstock, M. A., Harris, A. R., Hinckley, M. R., Feldman, S. R., Fleischer, A. B., & Coldiron, B. M. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.19 · Cited by 1,185
Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis
Boniol, M., Autier, P., Boyle, P., & Gandini, S. (2012) · BMJ · doi:10.1136/bmj.e4757 · Cited by 644
Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis
Wehner, M. R., Shive, M. L., Chren, M.-M., Han, J., Qureshi, A. A., & Linos, E. (2012) · BMJ · doi:10.1136/bmj.e5909 · Cited by 350
Screening for Skin Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Wolff, T., Tai, E., & Miller, T. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-3-200902030-00009 · Cited by 174
Screening for malignant melanoma: A cost-effectiveness analysis
Freedberg, K. A., Geller, A. C., Miller, D. R., Lew, R. A., & Koh, H. K. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70010-1 · Cited by 173
Economic evaluation of skin cancer prevention in Australia
Shih, S. T. F., Carter, R., Sinclair, C., Mihalopoulos, C., & Vos, T. (2009) · Preventive Medicine · doi:10.1016/j.ypmed.2009.09.008 · Cited by 104
Kyle, J., Hammitt, J. K., Lim, H. W., Geller, A. C., Hall-Jordan, L., Maibach, E. W., Fabo, E. C. D., & Wagner, M. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1400 · Cited by 93
Hirst, N. G., Gordon, L. G., Gies, P. H., & Green, A. C. (2008) · Health Policy · doi:10.1016/j.healthpol.2008.07.003 · Cited by 48
Cited by
Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012
Rogers, H. W., Weinstock, M. A., Feldman, S. R., & Coldiron, B. M. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1187 · Cited by 1,815
Islami, F., Goding Sauer, A., Miller, K. D., Siegel, R. L., Fedewa, S. A., Jacobs, E. J., McCullough, M. L., Patel, A. V., Ma, J., Soerjomataram, I., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21440 · Cited by 1,610
Bio-Integrated Wearable Systems: A Comprehensive Review
Ray, T. R., Choi, J., Bandodkar, A. J., Krishnan, S., Gutruf, P., Tian, L., Ghaffari, R., & Rogers, J. A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00573 · Cited by 1,350
A Phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention
Chen, A. C., Martin, A. J., Choy, B., Fernández-Peñas, P., Dalziell, R. A., McKenzie, C. A., Scolyer, R. A., Dhillon, H. M., Vardy, J. L., Kricker, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506197 · Cited by 648
Mechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
Metadata
- Authors
- Guy, G. P., Machlin, S. R., Ekwueme, D. U., & Yabroff, K. R.
- Venue
- American Journal of Preventive Medicine
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 48
- Issue
- 2
- Pages
- 183-187
- ISSN
- 0749-3797 (ISSN-L)
- OpenAlex
- W1971941564
- Cited by
- 873
- References
- 10
- FWCI
- 124.58
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 2007−2011. https://app.cochat.ai/papers/10.1016/j.amepre.2014.08.036
- The paper
- Guy, G. P., Machlin, S. R., Ekwueme, D. U., & Yabroff, K. R. (2015). Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 2007−2011. American Journal of Preventive Medicine. https://doi.org/10.1016/j.amepre.2014.08.036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
